CGRP Antibody

Eptinezumab Effectively Reduces Migraine Frequency in Phase 3 Trial

Eptinezumab Effectively Reduces Migraine Frequency in Phase 3 Trial

By

Eptinezumab, an investigational treatment for migraine prevention, has met its pivotal Phase 3 trial primary endpoint of significant reduction in monthly migraine days vs placebo.

Treatment With Monoclonal CGRP Antibody Reduces Number of Headache Hours

Treatment With Monoclonal CGRP Antibody Reduces Number of Headache Hours

By

Participants experienced a reduction in headache days as soon as 3 days post-treatment.

Sign Up for Free e-Newsletters